A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells

Biochemical and Biophysical Research Communications

Volumn 392, Issue 2, 2010, Pages 190-195

  Liu, Lin ^a   Chen, Baoan ^a   Qin, Shukui ^b   Li, Suyi ^a   He, Xiangming ^a   Qiu, Shaomin ^c   Zhao, Wei ^c   Zhao, Hong ^c  

^a SOUTHEAST UNIVERSITY   (China)

^b The 81st Hospital of PLA   (China)

^c Nanjing Municipal Tumor Hospital   (China)

Author keywords

Apoptosis; Chidamide; Colon cancer cells; HDAC inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; BETA ACTIN; CHIDAMIDE; CYCLIN DEPENDENT KINASE 4; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P21; RAF PROTEIN; RAS PROTEIN; S6 KINASE; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG DESIGN; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACETYLATION; AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL LINE, TUMOR; COLONIC NEOPLASMS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 75749143069     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.01.011     Document Type: Article

References (34)

1. Davie J.R. Covalent modification of histones: expression from chromatin templates. Curr. Opin. Genet. Dev. 8 (1998) 173-178
2. Khochbin S., Verdel A., Lemercier C., and Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr. Opin. Genet. Dev. 11 (2001) 162-166
3. Ropero S., and Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol. Oncol. 1 (2007) 19-25
4. Al-Janadi A., Chandana S.R., and Conley B.A. Histone deacetylation: an attractive target for cancer therapy?. Drugs R D 9 (2008) 369-383
5. Lee M.J., Kim Y.S., Kummar S., Giaccone G., and Trepel J.B. Histone deacetylase inhibitors in cancer therapy. Curr. Opin. Oncol. 20 (2008) 639-649
6. Marks P.A., and Jiang X. Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 4 (2005) 549-551
7. Marchion D., and Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev. Anticancer Ther. 7 (2007) 583-598
8. Martínez-Iglesias O., Ruiz-Llorente L., Sánchez-Martínez R., García L., Zambrano A., and Aranda A. Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin. Transl. Oncol. 10 (2008) 395-398
9. Xu W.S., Parmigiani R.B., and Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26 (2007) 5541-5552
10. Mehnert J.M., and Kelly W.K. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J. 13 (2007) 23-29
11. Cang S., Ma Y., and Liu D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J. Hematol. Oncol. 1 (2009) 22
12. Marks P.A., and Xu W.S. Histone deacetylase inhibitors: potential in cancer therapy. J. Cell Biochem. 107 (2009) 600-608
13. Hu E., Dul E., Sung C.M., Chen Z., Kirkpatrick R., Zhang G.F., Johanson K., Liu R., Lago A., Hofmann G., Macarron R., de los Frailes M., Perez P., Krawiec J., Winkler J., and Jaye M. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther. 307 (2003) 720-728
14. Vannini A., Volpari C., Filocamo G., Casavola E.C., Brunetti M., Renzoni D., Chakravarty P., Paolini C., De Francesco R., Gallinari P., Steinkühler C., and Di Marco S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA 101 (2004) 15064-15069
15. Wang D.F., Helquist P., Wiech N.L., and Wiest O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J. Med. Chem. 48 (2005) 6936-6947
16. Chen C.S., Weng S.C., Tseng P.H., Lin H.P., and Chen C.S. Histone acetylation-independent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 46 (2005) 38879-38887
17. Kobayashi Y., Ohtsuki M., Murakami T., Kobayashi T., Sutheesophon K., Kitayama H., Kano Y., Kusano E., Nakagawa H., and Furukawa Y. Histone deacetylase inhibitor FK228 suppresses the Ras-MAP kinase signaling pathway by upregulating Rap1 and induces apoptosis in malignant melanoma. Oncogene 4 (2006) 512-524
18. Ross P.J., George M., Cunningham D., DiStefano F., Andreyev H.J., Workman P., and Clarke P.A. Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides. Mol. Cancer Ther. 1 (2001) 29-41
19. Mallon R., Feldberg L., Kim S., Collins K., Wojciechowicz D., Kohler C., Kovacs D., Discafani C., Zhang N., Wu B., Floyd B., Powell D., and Berger D. Identification of 4-anilino-3-quinolinecarbonitrile inhibitors of mitogen-activated protein/extracellular signal-regulated kinase 1 kinase. Mol. Cancer Ther. 3 (2004) 755-762
20. Mitchell C., Kabolizadeh P., Ryan J., Roberts J.D., Yacoub A., Curiel D.T., Fisher P.B., Hagan M.P., Farrell N.P., Grant S., and Dent P. Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. Mol. Pharmacol. 72 (2007) 704-714
21. Ocker M., and Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int. J. Biochem. Cell Biol. 39 (2007) 1367-1374
22. Hsiao J.R., Leu S.F., and Huang B.M. Apoptotic mechanism of paclitaxel-induced cell death in human head and neck tumor cell lines. J. Oral. Pathol. Med. 38 (2009) 188-197
23. Dubrez L., Coll J.L., Hurbin A., de Fraipont F., Lantejoul S., and Favrot M.C. Cell cycle arrest is sufficient for p53-mediated tumor regression. Gene. Ther. 8 (2001) 1705-1712
24. Xu W.S., Perez G., Ngo L., Gui C.Y., and Marks P.A. Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res. 65 (2005) 7832-7839
25. Aubry J.P., Blaecke A., Lecoanet-Henchoz S., Jeannin P., Herbault N., Caron G., Moine V., and Bonnefoy J.Y. Annexin V used for measuring apoptosis in the early events of cellular cytotoxicity. Cytometry 37 (1999) 197-204
26. Robertson J.D., Orrenius S., and Zhivotovsky B. Review: nuclear events in apoptosis. J. Struct. Biol. 129 (2000) 346-358
27. Crisanti M.C., Wallace A.F., Kapoor V., Vandermeers F., Dowling M.L., Pereira L.P., Coleman K., Campling B.G., Fridlender Z.G., Kao G.D., and Albelda S.M. The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol. Cancer Ther. 8 (2009) 2221-2231
28. Andrews K.T., Tran T.N., Wheatley N.C., and Fairlie D.P. Targeting histone deacetylase inhibitors for anti-malarial therapy. Curr. Top. Med. Chem. 9 (2009) 292-308
29. Glauben R., Sonnenberg E., Zeitz M., and Siegmund B. HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett. 280 (2009) 154-159
30. Kang M.R., Kang J.S., Han S.B., Kim J.H., Kim D.M., Lee K., Lee C.W., Lee K.H., Lee C.H., Han G., Kang J.S., Kim H.M., and Park S.K. A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells. Biochem. Pharmacol. 78 (2009) 486-494
31. Carew J.S., Giles F.J., and Nawrocki S.T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett. 269 (2008) 7-17
32. Chiba T., Yokosuka O., Fukai K., Kojima H., Tada M., Arai M., Imazeki F., and Saisho H. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells. Oncology 66 (2004) 481-491
33. de Ruijter A.J., Meinsma R.J., Bosma P., Kemp S., Caron H.N., and van Kuilenburg A.B. Gene expression profiling in response to the histone deacetylase inhibitor BL1521 in neuroblastoma. Exp. Cell Res. 309 (2005) 451-467
34. Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T., Olsen J.V., and Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325 (2009) 834-840